Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Change in Accured Expenses data on file, last reported at $4.3 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 908.87% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $136.7 million, a 328.67% increase from a year earlier, with the FY2025 full-year figure at $131.9 million, up 279.96% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $4.3 million, up from -$88.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for MDGL reached as high as $187.5 million in Q3 2025 and fell as low as -$88.4 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $12.1 million across 5 years, with a median of $4.3 million in 2026.
• Across the five-year window, Change in Accured Expenses surged 1712.96% in 2024 and sank 1301.7% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $11.9 million in 2022, then sank by 37.87% to $7.4 million in 2023, then tumbled by 185.59% to -$6.3 million in 2024, then sank by 1301.7% to -$88.4 million in 2025, then surged by 104.85% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $4.3 million in Q1 2026, -$88.4 million in Q4 2025, and $187.5 million in Q3 2025.